Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind dosage, safety and immunogenicity trial of a bivalent norovirus VLP vaccine in infants and young children
2014-000778-20Phase 2Completed
- Sponsor
- Takeda
- Start
- Apr 2014
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of human norovirus bivalent (GI.1/GII.4) vaccine in Noroviral gastroenteritis (2 arms), sponsored by Takeda. Primary endpoint: Immunogenicity (primary). Started Apr 2014; status: completed.
02
Drugs
human norovirus bivalent (GI.1/GII.4) vaccine
03
Conditions
Noroviral gastroenteritis
Beyond the preview
Go deeper on 2014-000778-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000778-20.